You are here

psoriasis

Leo Pharma offloads a psoriasis asset as their Dupixent rival heads to the FDA

Endpoints

Tue, 07/21/20 - 10:27 am

Eli Lilly’s Mirikizumab Hits the Mark in Phase III Study, Bests Cosentyx

BioSpace

Sat, 07/18/20 - 12:17 pm

clinical trials

Amgen's Enbrel Patents to Be Upheld Through 2029

Motley Fool

Thu, 07/2/20 - 12:15 am

rheumatoid arthritis

UCB’s growth driver squares up against the competition

EP Vantage

Thu, 06/11/20 - 12:20 pm

clinical trials

Amgen ramps up Otezla expansion effort with positive data in mild psoriasis

Fierce Pharma

Thu, 05/7/20 - 12:27 am

Lilly spends big on mirikizumab

EP Vantage

Thu, 02/13/20 - 10:40 am

clinical trials

AbbVie Reports Successful Trial Results for Arthritis Drug

Motley Fool

Wed, 02/5/20 - 10:00 pm

clinical trials

AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis

Motley Fool

Wed, 01/15/20 - 10:56 am

Boehringer Ingelheim

Durect shares rocked by midstage psoriasis flop, shifts focus to liver disease

Fierce Biotech

Fri, 01/3/20 - 09:46 am

clinical trials

UCB posts more supportive data from Humira rival bimekizumab

Pharmaforum

Fri, 12/6/19 - 09:31 pm

Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla

Fierce Pharma

Thu, 11/21/19 - 06:29 pm

UCB adds on more positive PhIII data for IL-17A/17F inhibitor bimekizumab, clearing a path to the FDA

Endpoints

Fri, 11/15/19 - 11:12 am

clinical trials

Johnson & Johnson's Tremfya backs psoriatic arthritis play with newest data

Fierce Pharma

Tue, 11/12/19 - 10:03 am

psoriatic arthritis

clinical trials

J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis

BioSpace

Mon, 10/21/19 - 10:00 am

clinical trials

UCB's bispecific beats J&J's Stelara in psoriasis phase 3

Fierce Biotech

Fri, 10/18/19 - 07:47 pm

bispecific antibodies

UCB tries to win some respect in the crowded psoriasis market with a dual IL-17 approach — and it won't be easy

Endpoints

Thu, 10/17/19 - 10:24 am

Sienna Biopharmaceuticals Files for Bankruptcy, Delaying Phase III Psoriasis Trial

BioSpace

Wed, 09/18/19 - 06:59 pm

Sienna Biopharmaceuticals

Skyrizi looks ready to soar after strong launch

Biopharma Dive

Wed, 09/4/19 - 11:23 pm

Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger

Stat

Mon, 08/26/19 - 10:24 am

Bristol-Myers Squibb

5 Biggest New Drugs Approved in 2019 So Far

Motley Fool

Tue, 08/13/19 - 11:43 am

multiple sclerosis

metastatic bladder cancer

Pages